File this under “reversal of fortunes.”
Late last Friday, Momenta Pharmaceuticals disclosed that a Pfizer plant contracted to make a generic version of a best-selling multiple sclerosis medicine was slapped with a warning letter by the US Food and Drug Administration. This means Momenta will suffer an unspecified delay in winning approval to sell a larger dose of the drug than what is currently available and, consequently, will lose a chunk of a big market.
Now and again the hasty wisdom of Miles White to jettison the part of Abbott that became Hospira does need to be seen in a better light. But only now and again …
Comments are closed.